COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561	NDA	Gilead Sciences, Inc.	61958-1901-1	30 TABLET in 1 BOTTLE, PLASTIC (61958-1901-1)	2015-11-05
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

The pharmaceutical landscape for antiretroviral drugs has expanded significantly, driven by the global need for effective HIV management. Among these therapies, a combination of cobicistat, elvitegravir, emtricitabine, and tenofovir alafenamide fumarate (TAF) forms the backbone of several fixed-dose regimens, including Genvoya and Stribild. The procurement of these active pharmaceutical ingredients (APIs) is critical for drug manufacturers, biotech firms, and healthcare providers aiming to ensure supply chain stability, cost competitiveness, and compliance with regulatory standards. This report examines the current suppliers, manufacturing dynamics, and strategic considerations pertinent to these four drugs.

Cobicistat Suppliers

Cobicistat, a pharmacokinetic enhancer enhancing the bioavailability of co-administered antiretrovirals, is produced predominantly by leading pharmaceutical ingredient manufacturers. Major suppliers include:

Jiangsu Hengrui Medicine Co., Ltd. (China): A primary manufacturer, Hengrui supplies cobicistat internationally, leveraging advanced synthesis technologies and large-scale production facilities compliant with international quality standards [1].
Cipla Limited (India): Cited for its active pharmaceutical ingredient manufacturing capacities, Cipla has developed supply agreements with global pharma companies, ensuring competitive pricing and reliable delivery [2].
Gilead Sciences: While Gilead is the originator of cobicistat, it primarily supplies the drug as a finished product. The company does not typically manufacture APIs for third-party use but maintains strategic partnerships with API producers.

Manufacturing and Market Dynamics

The global API market for cobicistat is concentrated, with China and India producing the majority due to cost advantages and robust chemical manufacturing sectors. Regulatory barriers and quality control are pivotal, with suppliers required to meet standards such as the FDA's cGMP and EMA guidelines. Recently, increasing scrutiny on Chinese suppliers has led to more stringent qualification processes, impacting supply continuity [3].

Elvitegravir Suppliers

Elvitegravir is a potent integrase inhibitor, essential for combination therapies. Key suppliers include:

Janssen Pharmaceuticals: The originator of elvitegravir, Janssen manufactures both the API and fixed-dose combination products. Their global footprint ensures supply reliability but limits third-party API licensing [4].
Hetero Labs Ltd. (India): An established producer of antiretroviral APIs, Hetero has obtained licensing agreements to manufacture elvitegravir for multiple markets, especially in regions with local manufacturing preferences [5].
Macleods Pharmaceuticals: An Indian manufacturer with capacity for antiretroviral APIs, including demonstrated capabilities in synthesizing high-purity elvitegravir [6].

Manufacturing Considerations

Elvitegravir synthesis involves complex chemistries necessitating advanced process control, high-quality starting materials, and strict compliance with regulatory standards. Asia-based generic manufacturers have expanded their capacity to meet global demand, especially as patents have expired for certain combination formulations.

Emtricitabine Suppliers

Emtricitabine (FTC), a nucleoside reverse transcriptase inhibitor, boasts a mature manufacturing sector, leading to multiple reliable suppliers:

Hoffmann-La Roche (Switzerland): The original developer, Roche supplies the drug via their manufacturing facilities, with extensive global distribution channels.
Cipla Limited (India): A prominent generic manufacturer, Cipla produces emtricitabine at scale, supplying both bulk API and finished dosage forms.
Lupin Limited (India): With strong API manufacturing capabilities, Lupin supplies high-quality emtricitabine for generic markets [7].
Sun Pharmaceutical Industries Ltd. (India): A significant player, the company supplies APIs and finished products, competing on cost and quality.

Market Dynamics

The emtricitabine API market benefits from decades of experience, with multiple approved manufacturing sites worldwide. Quality assurance and regulatory compliance are well-established, facilitating rapid market entry and supply chain stability [8].

Tenofovir Alafenamide Fumarate (TAF) Suppliers

Tenofovir alafenamide fumarate (TAF), a prodrug providing improved safety profiles over tenofovir disoproxil fumarate (TDF), is produced by a limited number of specialized manufacturers:

Gilead Sciences: The patent holder and primary producer of TAF, Gilead maintains in-house manufacturing facilities that supply the API directly for their proprietary formulations.
Hetero Labs Ltd. (India): Licensed to produce TAF as part of Gilead’s global supply agreements, Hetero manufactures TAF API for several markets, benefitting from Gilead’s technical transfer and quality control protocols [9].
OctoPlus (The Netherlands): Specialized in prodrug synthesis, OctoPlus has partnered with Gilead for manufacturing TAF, though their role has been mostly in contract development and manufacturing.
Fertigyn Pharmaceuticals (India): Has announced strategic initiatives to manufacture TAF API, anticipating growing demand in generic formulations.

Supply and Regulatory Challenges

TAF manufacturing involves complex chemical processes with strict safety and quality standards. The limited number of licensed producers underscores a significant bottleneck, with Gilead and select Indian manufacturers dominating the market. The patent landscape, alongside ongoing efforts to develop biosimilar and generic TAF formulations, influences future suppliers’ entries [10].

Strategic Implications for Buyers and Stakeholders

Supply Chain Diversification: Relying on few suppliers, especially for TAF, exposes manufacturers to risks—political, regulatory, or capacity constraints. Strategic partnerships in India and China mitigate some risks but require rigorous qualification procedures.
Quality Assurance and Regulatory Compliance: Suppliers operating under cGMP conditions and with ISO certifications will better facilitate regulatory approvals internationally.
Cost Considerations: Asian suppliers offer competitive APIs prices, impacting formulation costs. However, quality and supply reliability must balance cost advantages.
Patent and Licensing Landscape: As patents expire or licensing agreements evolve, additional suppliers may enter the market, enhancing competitiveness.

Conclusion

The supply landscape for cobicistat, elvitegravir, emtricitabine, and tenofovir alafenamide fumarate involves predominantly Asian manufacturers along with established Western pharmaceutical corporations. The complexity of manufacturing processes and regulatory compliance requirements shape the market dynamics, mitigating risks for pharmaceutical companies seeking reliable sourcing. Strategic partnerships, procurement planning, and thorough qualification processes are vital to maintaining uninterrupted supply chains in the high-stakes context of antiretroviral therapy.

Key Takeaways

Market Concentration: China and India dominate API manufacturing for these HIV drugs, emphasizing the need for diversified supplier bases.
Quality and Regulatory Compliance: Due to the complexity of these APIs, suppliers must adhere to international quality standards, influencing procurement choices.
Emerging Competition: Patent expirations and licensing agreements are expanding the pool of potential suppliers, promising increased competition and cost savings.
Supply Chain Risks: Heavy reliance on limited suppliers for TAF necessitates careful risk management, including strategic inventory and qualification plans.
Future Trends: Increased regulatory scrutiny and technological innovations in synthesis may alter the supplier landscape, potentially reducing costs and increasing reliability.

FAQs

1. Who are the leading global suppliers for cobicistat API?
Chinese companies like Jiangsu Hengrui Medicine and Indian firms such as Cipla are prominent suppliers, leveraging cost-effective manufacturing while adhering to international standards.

2. Which companies produce elvitegravir for the generic market?
Hetero Labs and Macleods Pharmaceuticals are notable generic manufacturers licensed to produce elvitegravir, meeting global demand outside of branded formulations.

3. What considerations influence the choice of API suppliers for emtricitabine?
Quality assurance, regulatory compliance, cost, and manufacturing capacity are critical in selecting suppliers, with established providers like Roche, Cipla, and Lupin leading the market.

4. Are there any new entrants in the TAF API market?
Yes, Indian companies such as Fertigyn Pharmaceuticals are planning or have begun manufacturing TAF, expanding the supplier base amid growing demand.

5. How does patent status affect API supply for these drugs?
Patent expiration and licensing agreements can enable new suppliers to produce generics, increasing supply diversity and potentially lowering costs.

References

[1] Jiangsu Hengrui Medicine Co., Ltd. Official website.
[2] Cipla Limited Annual Report.
[3] FDA ICH Guidelines on API Quality Standards.
[4] Janssen Pharmaceuticals – Corporate Website.
[5] Hetero Labs Ltd. Licensing Agreements Overview.
[6] Macleods Pharmaceuticals Capacity Update.
[7] Lupin Limited API Portfolio.
[8] European Medicines Agency - APIs Market Overview.
[9] Gilead Sciences – TAF Manufacturing and Licensing Info.
[10] Patent Landscape Reports on TAF and related analogs.

Suppliers and packagers for generic pharmaceutical drug: COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE